Archives
-
Exercise Capacity Before Muscle Dysfunction in PH
2026-10-05
A 2024 rat study found that reduced exercise capacity can emerge with right-ventricular dysfunction before measurable intrinsic skeletal-muscle failure in pulmonary hypertension. The findings support a cardiopulmonary explanation for early exercise intolerance while showing that more severe disease may later coincide with muscle atrophy, without necessarily impairing mitochondrial respiration, force, or fatigue resistance.
-
Sodium Oxamate in Metabolic Signaling Research
2026-10-05
A source-grounded overview of Sodium Oxamate and Oxamic Acid as research tools for studying LDH-A, lactate biology, cancer metabolism, and immunometabolic signaling, with emphasis on what a 2026 BVDV study does—and does not—establish.
-
Geneticin (G418 Sulfate): Evidence and Limits
2026-10-04
Geneticin and G418 Sulfate are aminoglycoside research reagents used for selection through neomycin-resistance markers and for cell-based antiviral investigation. The evidence supports a clear distinction between supplier-reported G418 activity and peer-reviewed findings on HHT-driven ribotoxic stress, with no basis for assuming identical mechanisms or clinical efficacy.
-
Sphingosine-1-phosphate: From Receptor to Cell Fate
2026-10-03
Sphingosine-1-phosphate is a context-dependent lipid messenger whose effects vary with receptor subtype, cell state, and signaling network. This article interprets S1P biology through the contrast between S1PR1-mediated vascular signaling and S1PR3-associated neuronal apoptosis after intracerebral hemorrhage.
-
Protease Inhibitor Cocktail: EDTA-Free Workflow
2026-10-02
Protease degradation can reduce recovery, alter banding patterns, and disrupt protein-complex analysis during extraction and sample preparation. This EDTA-free cocktail is suited to lysates, Western blotting, co-immunoprecipitation, pull-downs, immunostaining, and phosphorylation-sensitive enzyme assays, but it should not be treated as a universal substitute for phosphatase inhibitors or metalloprotease control.
-
β-Pseudouridine for RNA Modification Workflows
2026-10-01
β-Pseudouridine enables controlled studies of RNA structure, translational fidelity, and epitranscriptomic regulation without confusing nucleoside chemistry with RNA platform architecture. This workflow-oriented guide covers stock preparation, structural assays, vaccine-platform comparisons, and troubleshooting for reliable interpretation.
-
D-Mannitol B2090: Practical Research Workflow
2026-10-01
D-Mannitol B2090 provides a defined, water-soluble reagent for controlled osmotic regulation, renal function studies, and diuretic mechanism investigation. It is intended for laboratory workflows rather than clinical treatment, and solutions should be prepared for near-term use because long-term solution storage is not recommended.
-
Cambinol: A Translational Probe for SIRT Biology
2026-09-30
SIRT1/2 Inhibitor IV (cambinol) offers a cell-permeable way to interrogate how NAD-dependent deacetylase activity intersects with acetylation, hypoxia, tumor biology, and metabolic signaling. This thought-leadership article connects established cambinol evidence with new findings on SIRT1-regulated Ran lactylation and highlights a disciplined path from mechanistic hypothesis to translational validation.
-
Rottlerin: PKCδ Signaling in Barrier Models
2026-09-30
Rottlerin is a PKC inhibitor whose cellular effects depend on both kinase selectivity and intracellular delivery. This guide connects PKCδ pharmacology with nanoparticle uptake and barrier-model design to improve interpretation of proliferation, apoptosis, and permeability assays.
-
TRPV1 Somatosensory Reflexes Suppress Inflammation
2026-09-29
The 2025 iScience study identifies a somato-autonomic reflex in which stimulation of TRPV1-positive peripheral afferents activates brainstem, adrenal, vagal, and splenic pathways to reduce inflammatory cytokine production. Its use of Nonivamide as a chemical TRPV1 stimulus, together with knockout and RNA-sequencing analyses, provides a mechanistic framework for studying neuroimmune regulation rather than treating TRPV1 activation as only a local sensory event.
-
Nonivamide: TRPV1 Assay Design Beyond Cancer
2026-09-29
Nonivamide is a capsaicin analog that connects TRPV1 pharmacology with cancer cell growth inhibition and sensory-neuron research. This guide develops an evidence-tiered assay strategy that distinguishes receptor activation, apoptosis, and tissue-context effects.
-
EdU Flow Cytometry Assay Kits: Practical Guide
2026-09-28
Measure active DNA synthesis with a denaturation-free Cy3 click-chemistry workflow that supports cell-cycle profiling, multiplexed phenotyping, and treatment-response studies. This guide translates the TJP3 breast-cancer findings into practical assay controls, workflow choices, and troubleshooting strategies.
-
10074-G5 for c-Myc-Driven Cancer Research
2026-09-28
Use 10074-G5 to test whether c-Myc/Max activity helps sustain aggressive cancer-cell phenotypes—not simply whether cells remain viable. This workflow connects dose response, target engagement, EMT-related readouts, apoptosis and cell-cycle analysis while keeping the esophageal adenocarcinoma evidence distinct from results in other models.
-
METTL14–SMN Control of m6A Homeostasis
2026-09-27
The study identifies methylarginine-dependent binding between SMN and METTL14 as a regulatory link between protein arginine methylation and mRNA m6A deposition. Its findings connect this interaction to DNA-repair gene expression and SMA-associated cellular sensitivity to DNA damage, while a mouse model indicates additional roles for METTL14 methylation in development and hematopoiesis.
-
Cinoxacin: UTI Activity, Pharmacokinetics, and Limits
2026-09-26
The 1982 review by Scavone, Gleckman, and Fraser brings together evidence that cinoxacin inhibits bacterial DNA synthesis and can achieve useful urinary exposure against susceptible gram-negative uropathogens. Its findings support research into urinary tract infection models while highlighting important limits: variable susceptibility, early-era resistance data, and pharmacokinetic changes with impaired renal function.